Matrix Partners China
Venture capitalBeijing · Seed–Late Stage
Investment thesis
The firm seeks outstanding entrepreneurs, whether starting out or building again, and has extensive experience backing first-time founders as well as companies still at the idea stage. It prioritizes the founder's mindset, track record and growth potential over polished presentation skills, favoring capital-efficient industry pioneers that can scale quickly. The firm prefers to engage founders early, ideally before a formal fundraise begins, and aims to be a company's first institutional investor and largest non-management shareholder. It remains flexible about seed-stage and later-stage opportunities and provides ongoing follow-on investment as portfolio companies' needs evolve.
Source: firm website, verified Aug 3, 2026.
What they invest in
from 3 of 3 portfolio companiesBiotech ×3AI & Machine Learning ×1Digital Health ×1FoodTech ×1Healthtech ×1New Materials ×1
HQs:China×1United States×1
Investments · 3 tracked
founders shown can be your intro pathGrandomics (希望组), founded in 2011, provides third-generation (long-read) sequencing services and big-data analysis for research institutions, clinical diagnostics, and bioinformatics.
AI & Machine LearningBiotechDigital HealthBeijing, CN
Co-investorsVitalbridge CapitalMarathon Venture Partners
Bota Bio operates a proprietary Biofoundry platform combining computational algorithms with biotechnology to accelerate design-build-test-learn cycles for bio-manufacturing.
BiotechFoodTechNew Materials
Co-investorsHongShan Capital GroupNSG VenturesSource Code CapitalSherpa Healthcare Partners
Tallac Therapeutics is a biopharmaceutical company developing oligonucleotide-based antibody drug conjugates (ADCs) to treat cancer, including its Toll-like Receptor Agonist Antibody Conjugates (TRAAC) that deliver a TLR9 agonist to activate immune responses within the tumor microenvironment.
BiotechHealthtechBurlingame, US
Co-investorsLightstone VenturesMRL Ventures FundvenBio PartnersvenBio Global Strategic
Frequently asked questions
- What stage does Matrix Partners China invest at?
- Matrix Partners China invests at the Seed, Series A, Series B, Growth, Late Stage stages.
- What is Matrix Partners China's typical check size?
- Matrix Partners China typically writes checks of $1.6M – $113M.
- What sectors does Matrix Partners China focus on?
- Matrix Partners China focuses on AI & Machine Learning, Biotech, Consumer, Deep Tech, Enterprise Software, Hardware, Healthtech, Media & Entertainment, SaaS, Sector Agnostic.
- Where is Matrix Partners China located?
- Matrix Partners China is headquartered in Beijing, CN.
- Does Matrix Partners China lead rounds?
- Yes, Matrix Partners China leads investment rounds.
Similar investors
Industrial Technology Investment Corporation is the venture capital arm of Taiwan's Industrial Technology Research Institute (ITRI), backing startups across multiple stages and sectors while providing access to ITRI's R&D resources.
The Alibaba Entrepreneurs Fund is a not-for-profit initiative of Alibaba Group that provides investment capital and strategic guidance to entrepreneurs and young people, focusing on Hong Kong and Taiwan-nexus startups.
Venture Science is an investment firm applying research, mathematics, and decision theory to venture capital and public markets, powered by its proprietary in-house AI platform called Helix and its evergreen flagship fund Strata.
Olive Tree Capital invests in technology and life sciences companies, backing entrepreneurs across healthcare, fintech, enterprise, AI/ML, and frontier technology sectors.
Metaplanet is an evergreen investment firm that backs mission-driven founders building deep technologies aimed at supporting humanity's long-term survival and flourishing.